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Abstract
The World Allergy Organization (WAO) Guidelines for the assessment and management of anaphylaxis provide a
unique global perspective on this increasingly common, potentially life-threatening disease. Recommendations
made in the original WAO Anaphylaxis Guidelines remain clinically valid and relevant, and are a widely accessed and
frequently cited resource. In this 2015 update of the evidence supporting recommendations in the Guidelines, new
information based on anaphylaxis publications from January 2014 through mid- 2015 is summarized. Advances in
epidemiology, diagnosis, and management in healthcare and community settings are highlighted. Additionally, new
information about patient factors that increase the risk of severe and/or fatal anaphylaxis and patient co-factors that
amplify anaphylactic episodes is presented and new information about anaphylaxis triggers and confirmation of
triggers to facilitate specific trigger avoidance and immunomodulation is reviewed. The update includes tables
summarizing important advances in anaphylaxis research.
Keywords: Anaphylaxis, Epinephrine, Auto-injector, Food allergy, Stinging insect venom allergy, Drug allergy, Latex
allergy, Exercise-induced anaphylaxis, Systemic allergic reaction, Adrenaline
Introduction
The World Allergy Organization (WAO) Guidelines for
the Assessment and Management of Anaphylaxis remain
a clinically relevant, widely accessed, and frequently
cited resource [1]. This 2015 Update is intended for use
in conjunction with these WAO Anaphylaxis Guidelines,
the 2012 and 2013 Updates of the evidence supporting
the Guidelines, and the 2014 International Consensus
on (ICON): Anaphylaxis, a publication with a broader
mandate than the Updates [2–4].
Here, we review research published in peer-reviewed
indexed journals from January 2014 through mid-2015 on
the epidemiology of anaphylaxis, patient risk factors, amp-
lifying co-factors, triggers, diagnosis, and management in
healthcare and community settings. We also highlight ex-
cellence in clinical and translational research relevant to
anaphylaxis and cite major publications from other
allergy/immunology professional organizations [5, 6] and
different global regions.
Epidemiology
Updated information about the epidemiology of ana-
phylaxis, a life-threatening systemic or hypersensitivity
reaction with sudden onset, comes from general popula-
tion surveys and secondary analyses of large clinical and
administrative databases [7–16] (Table 1).
The lifetime risk of symptoms suggestive of anaphyl-
axis in the general population, as reported by members
of the public, is at least 1.6 %. This estimate is based on
a survey of 1000 unselected US adults with a sudden-
onset illness involving two or more body organ systems,
including the respiratory and/or cardiovascular systems,
who sensed their lives were in danger and received hos-
pital care [8].
The frequency of hospital admissions for anaphylaxis is
increasing. Information obtained from the US Healthcare
Cost and Utilization Project Kids’ In-Patient Database
consisting of a stratified random sample of 12,039,432
hospital discharges indicated that admissions for food-
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induced anaphylaxis in children aged <18 years more
than doubled from 2000 to 2009, with corresponding
increases in associated healthcare costs [9]. Similarly,
analysis of the Italian Ministry of Health database re-
vealed that hospitalizations for food-induced anaphyl-
axis in children increased year-on-year from 2006
through 2011. The increase was more pronounced in
those aged 5–14 years than in those age 4 years or
younger [10]. Time trends in Australian hospitalization
rates for food-induced anaphylaxis indicate that admis-
sions continue to increase across all age groups. Al-
though the highest hospitalization rates occurred in
children age 0–4 years, the greatest acceleration in the
rates of increase was found in the age groups 5–14 years
and 15–29 years [11].
In England and Wales, hospital admissions from all-
cause anaphylaxis increased by 615 % from 1992 to
2012; however, fatalities, checked against a prospective
fatal anaphylaxis registry, remained stable at 0.047 cases/
million population. Admission rates and fatality rates for
anaphylaxis from drugs and insect stings were highest in
the elderly. Admission rates for food-induced anaphyl-
axis were highest in young people, with a sharp peak in
the incidence of food anaphylaxis fatalities in the second
and third decades of life [12].
From 1999 to 2009, although hospitalizations for
anaphylaxis increased in the USA (annual percentage
change 2.2 %), this contrasted with a decreased case fatal-
ity rate among emergency department (ED) patients and
hospitalized patients (annual percentage change −2.35 %).
Overall mortality rates ranged from 0.63 - 0.76/million
population (186–225 deaths per year) and appeared stable
during the decade studied [13]. In another review of 2458
anaphylaxis fatalities from 1999 to 2010, drugs (58.8 %)
were the most common trigger followed by unspeci-
fied inducers (19.3 %), venoms (15.2 %) and foods
(6.7 %). Fatalities were associated with older age and
other demographic factors [14].
Anaphylaxis has been misclassified in both the Inter-
national Classification of Diseases (ICD)-9 and ICD-10
versions. The global allergy community views the 11th
revision, ICD-11, as an opportunity to improve the
classification and coding of hypersensitivity/allergic dis-
eases and is aiming to have a specific chapter on these
diseases included to facilitate future epidemiological
studies [15, 16].
Patient risk factors and amplifying co-factors in
anaphylaxis
Many publications now include information on patient
risk factors and amplifying co-factors in anaphylaxis
[17–37] (Table 1). These risk factors and co-factors dif-
fer from one age group to another. They are not yet op-
timally studied in the pediatric population.
In infancy, there is a paucity of anaphylaxis data because
of under-recognition and under-diagnosis due to age-
unique symptom patterns. In order to increase awareness
of anaphylaxis in this age group, illustrated pathways for
clinical diagnosis, management and prevention of recur-
rences in infants have been developed [19], based on the
WAO Guidelines [1].
In teenagers, there is an increased risk of severe and/
or fatal anaphylaxis, as reported in several different
types of studies. For example, in those who developed
life-threatening anaphylaxis during food oral immuno-
therapy (OIT) studies, relevant endogenous risk factors
included being an adolescent and having uncontrolled
asthma, while relevant exogenous co-factors included
lack of compliance with asthma preventer medications
and/or with OIT protocols, in addition to exercise, fast-
ing, denial of symptoms, and delay in seeking help [20].
In pregnancy, anaphylaxis is uncommon, but poten-
tially catastrophic because it can place mothers and in-
fants at high risk for hypoxic-ischemic encephalopathy
or death. Performing skin tests and challenge tests and
initiating allergen immunotherapy are typically avoided
because of the associated small, although definite, risk of
anaphylaxis. A new algorithm for the investigation of
anaphylaxis to RhD immunoglobulin G (anti-D) has
Table 1 Epidemiology and patient risk factors
Epidemiology [7–16]
Hospitalization rates for anaphylaxis continue to increase
year-on-year [9–12].
Anaphylaxis fatality rates have remained stable or decreased slightly.
Fatalities are age-, co-morbidity-, and trigger-related [12–14].
The highest hospital admission rates for food-induced anaphylaxis occur
in very young children age 0–4 years; however, the rate of increase in
the age groups 5–14 years and 15–29 years is accelerating [11].
Patient risk factors and amplifying co-factors [17–37]
Data from an anaphylaxis registry of more than 5000 patients with
systemic allergic reactions indicated that although monotherapy with
beta-blockers and to a lesser extent, ACE inhibitors, increased the risk of
severe anaphylaxis, the risk was further increased by concurrent use of a
drug from each class [26].
In an experimental model, although a beta-blocker (metoprolol) given
alone had a modestly aggravating effect and an ACE inhibitor (ramipril)
given alone had no significant effect, anaphylaxis was exacerbated and
mediator release was increased when these medications were given
concurrently [26].
In vitro, FcεRI-mediated mast cell histamine release was not
increased by metoprolol or ramipril given alone, but was synergistically
increased when the drugs were given together. This three-part study
provides epidemiologic and experimental evidence that ACE inhibitors and
beta-blockers aggravate anaphylaxis partly as a result of direct mast cell
priming and decreasing the threshold for mast cell activation [26].
In a prospective study of co-factors that amplify anaphylaxis,
wheat-dependent, exercise-induced anaphylaxis occurred when
plasma gliadin levels were elevated by ingestion of higher gluten
doses, gluten and exercise, or gluten and acetylsalicylic acid plus
alcohol [36].
ACE angiotensin-converting enzyme inhibitor
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been proposed to minimize the need for anti-D challenges
in pregnant Rh-negative women. It includes a detailed his-
tory, limited skin testing, and fetal Rh genotyping from
maternal blood [1, 2, 21].
Old age, combined with co-morbidities such as cardio-
vascular disease (CVD) and chronic obstructive pulmonary
disease, is an important risk factor for severe anaphylaxis
with hospitalization, prolonged hospital stay, and fatality
[12, 14, 17, 18, 22, 23]. Some widely used life-saving medi-
cations for CVD such as beta-blockers and angiotensin-
converting enzyme (ACE) inhibitors appear to increase the
risk of, or severity of, anaphylaxis; however, their interac-
tions and mechanisms of action are still incompletely
understood [23–25].
In a registry involving more than 5000 patients with
acute allergic reactions, there was a higher risk of severe
anaphylaxis in patients taking a beta-blocker and an
ACE inhibitor concurrently than when a beta-blocker or
an ACE inhibitor were given alone [26]. These findings
were confirmed in an experimental model in which
metoprolol given alone had some aggravating effect and
ramipril given alone had no significant effect, but
anaphylaxis symptoms were exacerbated and mediator
release was increased when they were given in combin-
ation [26]. In vitro, FcεRI-mediated mast cell histamine
release was increased by metoprolol and ramipril given
together, whereas these substances had no significant ef-
fect when given alone; the mechanism likely involved
direct mast cell priming and a decrease in the threshold
for mast cell activation [26].
Systemic mastocytosis may predispose to severe life-
threatening anaphylaxis. Although many patients with
this disorder have few or no mediator-related symptoms,
others have recurrent episodes of severe anaphylaxis
with clear signs of a mast cell activation syndrome
(MCAS). Some patients with systemic mastocytosis have
IgE-dependent symptoms; however, the severity and fre-
quency of MCAS reactions do not correlate with specific
IgE levels, basal tryptase levels, or the burden of neo-
plastic mast cells [27]. Other patients have unexplained
recurrent episodes of severe anaphylaxis with CVD
symptoms such as syncope and elevated basal tryptase
levels (>11.4 mcg/L) [28].
Patients who have indolent systemic mastocytosis
(ISM) without skin signs, and anaphylaxis triggered ex-
clusively by insect stings, have clinical and laboratory
features that differ significantly from other patients with
ISM. In this distinct subgroup, males predominate, basal
tryptase levels are not greatly elevated, KIT mutations
are frequently restricted to bone marrow mast cells, and
there are few bone marrow mast cell aggregates [29].
A rapid inexpensive screening test for the KIT
D816V mutation in peripheral blood has been devel-
oped. This test facilitated recognition of systemic
mastocytosis in 4/113 consecutive adult patients with
anaphylaxis who had normal or low basal serum tryp-
tase levels and absent or inconspicuous urticaria pig-
mentosa skin lesions [30].
More studies on elevation of basal levels of mediators
as a risk factor for anaphylaxis are being published. Ele-
vated tryptase levels are found to be a good marker for
predicting Hymenoptera venom-induced anaphylaxis
[31]. In a controlled study, low basal levels of platelet-
activating factor (PAF) acetylhydrolase (leading to in-
creased PAF levels) were also associated with severe
venom anaphylaxis [32]. A large extended family with
Mendelian inheritance of elevated basal tryptase levels
included members with MCAS, anaphylaxis, atopy, and
connective tissue abnormalities [33].
Co-factors, including exercise, ethanol, non-steroidal
anti-inflammatory drugs (NSAIDs), acute infections,
stress, and perimenstrual status potentially amplify ana-
phylaxis by decreasing the threshold of allergen expos-
ure (the allergen “dose”) needed to trigger anaphylaxis
and by amplifying the risk of anaphylaxis in patients
with low or borderline allergen sensitization [20, 34–37].
The proposed pathophysiologic mechanisms underlying
EIA require prospective testing [35]. As an example, in a
controlled study in 16 adults with a history of wheat-
dependent, exercise-induced anaphylaxis (WDEIA) and
omega-5-gliadin-specific IgE, prospective oral food chal-
lenges (OFCs) with increasing amounts of gluten alone, or
in combination with one or more co-factors, were per-
formed until symptoms developed. Plasma gliadin
levels were elevated by higher gluten doses, gluten and
exercise, or gluten and acetylsalicylic acid (ASA) plus
alcohol. Positive plasma gliadin threshold levels dif-
fered by more than 100-fold (median 628 pg/mL,
range 15–2111). In some patients, exercise was not an
essential trigger for symptoms [36].
Perimenstrual anaphylactic episodes in girls and
women are attributed to various mechanisms such as
hypersensitivity to progesterone or prostaglandin. Estro-
gen might also play a role by enhancing endothelial ex-
pression of nitric oxide synthase and nitric oxide
production, increasing vascular permeability, and inten-
sifying anaphylaxis severity [37].
Triggers of anaphylaxis
Globally important triggers (inducers) of anaphylaxis
such as foods, stinging insect venoms, and drugs remain
a major research focus [38–77] (Table 2).
In a large European registry study, standardized data are
being collected from patients with anaphylaxis referred to
allergy/immunology clinics, facilitating accurate compari-
son of triggers, symptom patterns, and treatment trends
across countries [38].
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Food-induced anaphylaxis
The immunopathology of food-induced anaphylaxis,
tests to confirm specific triggers, and approaches to
management have been reviewed in depth [39, 40].
Foods are by far the most common anaphylaxis trigger
in infants, children, teens, and young adults [9–12]. As
reported in a meta-analysis of data from 34 studies, the
incidence rate of food-induced anaphylaxis was 0.14 per
100 person-years at all ages, and up to 7 per 100 person-
years in children aged 0–4 years [41].
In a retrospective study of 168 adults aged >18 years
with new-onset food allergy, symptoms typically began
in the second and third decades; 49 % of these patients
reported anaphylaxis. Shellfish, tree nuts, fish, soy,
and peanut accounted for most cases, although many
other foods were implicated [42].
A 3 year follow-up study in 80 children with ED
visits for systemic allergic reactions (SARs) to foods
who had 116 repeat ED visits confirmed that severity
of previous reactions did not predict severity of subse-
quent reactions [43].
In the past two decades, cashew has become an im-
portant allergen due to increased consumption. Like
other tree nuts and peanuts, it contains potent allergens
that can trigger severe anaphylaxis when ingested in
trace amounts. Cross-reactivity with pistachio is re-
ported [39, 44].
In a prospective controlled study, 10 of 12 patients
with a history of urticaria after ingestion of mammalian
meat developed reactions ranging from urticaria to ana-
phylaxis within 3–7 hours of an open OFC with meat.
Basophil activation (increased CD63 expression) corre-
lated with symptom onset, likely reflecting antigen (gal-
actose-alpha 1,3-galactose [alpha-gal]) appearance in the
blood. None of the 13 control subjects developed symp-
toms [45].
In patients with alpha-gal-induced anaphylaxis, pork
kidney elicited symptoms and positive skin prick tests
(SPT) more consistently than pork muscle meat, attrib-
uted to higher alpha-gal concentrations (or more ac-
cessible alpha-gal epitopes) in pork kidney compared
with muscle. Co-factors, including alcohol, NSAIDs,
and exercise amplified low levels of sensitization to
alpha-gal [34].
Anaphylaxis has been reported from Japan in patients
who ingested okonomiyaki pancakes made from mite-
contaminated pancake mix and who had elevated specific
IgE to Dermatophagoides and Tyrophagus species [46].
In pharmaceutical formulations and other manufac-
tured products, foods and food derivatives used as excip-
ients include: egg protein, egg lecithin, fish protamine,
fish oil, gelatin (bovine or porcine), casein, lactalbumin,
lactose, peanut oil, sesame oil, soy lecithin, soy oil, and
soy phosphatidylcholine [47]. Anaphylaxis has been re-
ported in children with milk allergy and asthma treated
with lactose-containing intravenous (IV) formulation of
methylprednisolone sodium succinate [48], and life-
threatening anaphylaxis has been reported after topical
exposure to casein in an Everlast kickboxing glove [49].
Insect sting or bite-induced anaphylaxis
Many people in the general population who have toler-
ated previous insect stings are sensitized to Hymenop-
tera venom [50, 51]. In a prospective study to test the
relevance of asymptomatic sensitization, 94 such individ-
uals had venom skin tests (prick and intradermal), spe-
cific IgE levels, component-resolved diagnosis, and
basophil activation tests (BATs), followed by physician-
supervised challenge stings from one or more live in-
sects. Large local reactions occurred in 43.6 % (a 9.5-fold
Table 2 Food, insect sting, and drug/iatrogenic triggers
Food [34, 38–49]
In a prospective study, 10/12 patients with IgE-mediated mammalian
meat-induced systemic allergic reactions had OFCs with meat. Symptom
onset occurred in 3–7 hours and correlated with basophil activation
and increased CD63 expression, likely reflecting the appearance of
galactose-alpha 1,3-galactose (alpha-gal) in the blood. Controls remained
asymptomatic after OFCs [45].
Attributed to higher alpha-gal concentrations (or more accessible
alpha-gal epitopes), pork kidney elicited symptoms and positive skin tests
more consistently than pork muscle meat. Co-factors, including alcohol,
NSAIDs, and exercise, amplified low levels of alpha-gal sensitization [34].
Hymenoptera Venom [50–54]
The relevance of asymptomatic sensitization to Hymenoptera venom
was tested in 94 people who had previously tolerated field stings
without a systemic allergic reaction. On screening, they had elevated
venom-specific IgE levels. They underwent a complete evaluation
(skin tests, component-resolved diagnosis, BATs, and physician-supervised
insect sting challenges). Large local reactions occurred in 43.6 %,
and systemic reactions occurred in 5.3 %. Current venom allergy
tests did not distinguish asymptomatic sensitization from risk of
local or systemic reactions [52].
The predictive value of in vitro tests with Hymenoptera venoms can be
improved by use of recombinant venom allergens and component
resolved testing, for example, by utilizing a panel of honeybee allergens
that are free from cross-reactive carbohydrate determinants [53, 54].
Drugs/Iatrogenic Agents [55–77]
The health consequences of penicillin “allergy” included costly longer
admissions, greater use of broad-spectrum antibiotics, and increased
prevalence of serious infections with Clostridium difficile, methicillin-resistant
Staphylococcus aureus, and vancomycin-resistant enterococci [58].
Risk factors for fatal anaphylaxis to a neuromuscular blocker included
male sex, emergency setting, CVD/hypertension, concurrent beta-blocker
treatment, and obesity [71].
Of 228 consecutive patients with perioperative anaphylaxis, 9.6 % were
sensitized to the antiseptic/disinfectant chlorhexidine, as determined
using specific IgE measurements, basophil activation tests, and
standardized skin tests [73].
alpha-gal galactose-alpha 1,3-galactose; BATs basophil activation tests, CVD
cardiovascular disease, NSAIDs non-steroidal anti-inflammatory drugs; OFCs oral
food challenges
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increased risk versus asymptomatic, unsensitized individ-
uals), and SARs occurred in 5.3 %, suggesting that cur-
rently available tests cannot distinguish asymptomatic
sensitization from the risk of large local reactions or
SARs [52].
Patients who are clinically allergic to Hymenoptera
venom yet have absent or undetectable venom-specific
IgE can be identified by measuring serum IgE to a panel
of recombinant honeybee and yellow jacket venom aller-
gens (rVes v 1, rVes v 2, rVes v 3, and rVes v 5, and rApi
m 1, rApi m 2, rApi m 3 and rApi m 5). Use of recom-
binant allergens significantly increases test sensitivity, as
compared with specific IgE measurements to commer-
cial venom extracts [53].
Improved in vitro tests for patients with honeybee
venom allergy are being developed. Analysis of a panel of
cross-reactive carbohydrate determinant-free honeybee
venom allergens improved diagnostic sensitivity compared
with use of rApi m 1 alone, identified additional major al-
lergens, and revealed sensitization to allergens that have
been reported to be absent or under-represented in com-
mercial venom extracts [54].
Drug-induced anaphylaxis
Drugs, most commonly antibiotics, NSAIDs, and neuro-
muscular blocking agents (NMBAs), are frequent trig-
gers of anaphylaxis. Drug-induced anaphylaxis is under-
recognized. It can also be over-diagnosed based on his-
tory alone. Allergy/immunology evaluations are under-
utilized. Immediate reactions occurring within one hour
after dosing are typically mediated by specific IgE. Skin
testing is validated for beta-lactam antibiotics, but less
so for other antibiotics and for other drug classes. Drug
provocation tests are useful in selected patients [55–57].
A history of penicillin “allergy” has important health
consequences. In a cohort of 51,582 hospitalized US pa-
tients versus matched controls, those with a history of
penicillin “allergy” had significantly longer admissions,
greater use of broad-spectrum antibiotics including fluor-
oquinolones, clindamycin, and vancomycin, and increased
prevalence of serious infections including Clostridium dif-
ficile, methicillin-resistant Staphylococcus aureus, and
vancomycin-resistant enterococcal infections [58]. In a
UK teaching hospital, the total cost of antibiotics pre-
scribed for patients reporting “penicillin allergy” was 1.8
to 2.6-fold higher than for first-line antibiotics [59].
Assessment by history and skin tests can rule out the
likelihood of an acute allergic reaction to penicillins in
90-95 % of patients with a history of penicillin allergy,
potentially leading to large cost savings in health sys-
tems. Skin testing with commercially available benzyl
penicilloyl-polylysine (PrePen), previously validated in
adults, has now also been validated in children [60].
Physician-documented cephalosporin anaphylaxis is
rare. In a large US healthcare system, anaphylaxis oc-
curred during only five oral cephalosporin exposures
among 901,908 oral courses and during only eight paren-
teral cephalosporin exposures among 487,630 parenteral
courses [61].
Although many penicillin-allergic patients can tolerate
aztreonam or carbapenems, rare cross-reactivity between
penicillins and these drugs has been reported. Of 212
consecutive patients with a penicillin allergy history and
positive skin tests to one or more penicillins, all had
negative skin tests to aztreonam and three carbapenems
(imipenem-cilastatin, meropenem, and ertapenem). Of
the 211 patients who consented to challenge, all passed.
Pre-treatment skin tests with aztreonam and carbapen-
ems are nevertheless still recommended because nega-
tive tests indicate tolerability [62].
In contrast, skin tests cannot be relied on to con-
firm hypersensitivity to quinolones. Drugs such as
moxifloxacin frequently produce positive skin test
responses in healthy individuals, and testing with high
concentrations does not distinguish between patients
with a history of reactions and control patients who
have been exposed [63].
Few cases of anaphylaxis to macrolide antibiotics such
as erythromycin or clarithromycin have been reported to
date. Azithromycin-induced anaphylaxis has been con-
firmed by skin testing in three children [64].
NSAIDs are major triggers of anaphylaxis [65, 66]. In
the Portuguese Pharmacovigilance system, over 4 years,
they were responsible for 47.9 % of drug-induced ana-
phylaxis episodes and 25.6 % of anaphylaxis recurrences.
Implicated drugs included preferential COX-1 inhibitors
such as ASA, diclofenac, ibuprofen, naproxen, and, un-
commonly, weak COX-1 inhibitors such as paracetamol
(acetaminophen) [66].
Nine cases of IgE-dependent anaphylaxis to diclofenac
were recorded over a decade by the Allergy Vigilance
Network in France. Sensitization to diclofenac was con-
firmed in four of these patients by positive intradermal
tests, in one patient who developed acute urticaria after
intradermal testing, and in one skin test-negative patient
who developed anaphylaxis after an oral challenge with
diclofenac. The investigators emphasized the need for
development of tests to measure specific IgE to frequently
used NSAIDs such as diclofenac and ibuprofen [67].
Administration of any drug by any route can poten-
tially cause anaphylaxis. As an example, 3.5 % of 230 pa-
tients developed anaphylaxis within one hour of
subcutaneous injection of the plasma kallikrein inhibitor
ecallantide. There was no consistent association with IgE
to ecallantide or to Pichia pastoris, the yeast cells in
which ecallantide is produced by recombinant DNA
technology [68].
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Hypersensitivity reactions ranging from mild skin re-
actions to life-threatening anaphylaxis from biological
agents such as rituximab, trastuzumab, cetuximab, ofa-
tumumab, tocilizumab, and brentuximab are increasing
in frequency as use of these potentially life-saving agents
increases in neoplastic, auto-immune and inflammatory
diseases. Desensitization enables patients to receive a full
treatment regimen of these agents without developing
anaphylaxis [69].
Perioperative anaphylaxis, a serious complication, is re-
ported in up to 1/13,000 anesthetics. It can be caused by
NMBAs such as atracurium, suxamethonium, rocuronium,
or vecuronium; or by antibiotics, blood and blood products,
dyes, chlorhexidine, or natural rubber latex. In a prospective
study, 13 of 4595 (1 in 353) patients having a general
anesthetic met referral criteria for investigation of peri-
operative anaphylaxis, suggesting that the problem is
under-diagnosed [70]. From 2000 to 2011, 2022 cases of
NMBA anaphylaxis, 84 (4.1 %) of which were fatal, were re-
ported to the French National Pharmacovigilance Network.
Independent risk factors associated with death were: male
gender, emergency setting, history of hypertension or other
CVD, ongoing beta-blocker treatment, and obesity [71].
In 14 of 15 patients with perioperative anaphylaxis due
to sugammadex injection for reversal of neuromuscular
blockade, symptoms began within four minutes of the
sugammadex injection [72].
Chlorhexidine, an antiseptic/disinfectant active against
a broad spectrum of bacteria, viruses, and fungi, is an in-
creasingly common anaphylaxis trigger found in skin
cleansers, central venous lines, urinary catheters, and
other products. Chlorhexidine sensitization was identi-
fied in 9.6 % of 228 patients with perioperative anaphyl-
axis by using specific IgE measurements, BAT, and
standardized SPT and intradermal tests [73].
Natural rubber latex allergy remains an important ana-
phylaxis trigger in many countries. In Israel, prospective
use of a 9-item written screening questionnaire before
elective Caesarean delivery identified potential clinical re-
activity to latex in 14.6 % of 453 women, compared with
identification of potential reactivity in only 2.6 % of 460
women who answered a standard verbal inquiry [74].
Of 104 patients with iodinated radiocontrast media
(RCM)-induced anaphylaxis, 34.6 % developed it on
their first RCM exposure. Patients presenting with shock
were older and had more frequent RCM exposures.
In the 51 patients who were skin tested, the overall posi-
tivity rate was 64.7 % and in those with shock, it was
81.8 % [75].
Although gadolinium-based contrast agents are rec-
ommended in patients with a history of RCM-induced
anaphylaxis, they, too, can trigger anaphylaxis. Of 614
cases reported to the US Food and Drug Administra-
tion’s Adverse Event Reporting System, 43 % were
associated with gadopentetate dimeglumine, 29 % with
gadobenate dimeglumine, and 17 % with gadoteridol [76].
In a case series of anaphylaxis to IV fluorescein, the
most common presentation was hypotension, typically
occurring within three minutes of dye infusion [77].
Diagnosis of anaphylaxis
Diagnosis of anaphylaxis depends on recognition of
characteristic symptoms and signs that occur minutes to
hours after exposure to a known or potential trigger [1].
High-quality studies relevant to clinical diagnosis and la-
boratory tests to support the diagnosis of anaphylaxis
are being published [78–90] (Table 3).
The major anaphylaxis guidelines include the Na-
tional Institute of Allergy and Infectious Diseases clin-
ical criteria for diagnosis, a practical instrument for
rapid identification of patients with a likely diagnosis of
Table 3 Diagnosis, initial treatment, and self-treatment in
community settings
Diagnosis [78–90]
In a prospective controlled study of ED patients with anaphylaxis,
up-regulation of innate inflammatory gene networks was reported.
On ED arrival, two genes were expressed; one hour after arrival, 67
genes were expressed; and three hours after arrival, 2801 genes
were expressed. Genomic responses provide new insights into the
potential release of a cascade of mediators in anaphylaxis [90].
Initial treatment [91–103]
Early injection of epinephrine in anaphylaxis, defined as initial injection
before ED arrival, significantly reduced the likelihood of hospital admission,
compared with initial epinephrine injection after ED arrival [92].
Epinephrine was injected before cardiac arrest in only 23 % of 92
individuals who experienced a fatal anaphylaxis episode [93].
In an observational study, data confirmed the safety of IM epinephrine
injection, typically given through an epinephrine auto-injector: (adverse
events 1 %, and no overdoses). In contrast, IV bolus injections were
associated with significantly more adverse events (10 %) and overdoses
(13 %) [99].
In a systematic review and meta-analysis of 27 studies, 4.7% of 4114
patients with anaphylaxis had biphasic episodes (range 0.4% to 23.3%).
Patients who presented with hypotension or who had an unknown
inciting trigger were at increased risk. The data suggested that for
patients with anaphylaxis who are treated successfully in an ED, the
duration of observation should be risk-stratified according to the
clinical characteristics and severity of the episode [101].
Long-term management: self-treatment in community settings
[104–118]
Patients who were treated in an ED for anaphylaxis benefited from
referral to A/I specialists who clarified the diagnosis and correctly
identified and confirmed specific anaphylaxis triggers [104].
Novel EAIs are now available in some countries. The compact Auvi-Q
can be used correctly on first attempt by 93 % of parents who have
never seen or heard it before. The Emerade is available in 0.15 mg,
0.3 mg, and 0.5 mg doses. The 0.3 mg and the 0.5 mg dose EAIs have a
25 mm long needle. EAIs differ significantly with regard to size, ease of
carrying, ease of use, needle protection, and robustness. They are not
interchangeable [107, 108].
A/I allergy/immunology, ED emergency department, EAI epinephrine auto-
injector, IM intramuscular, IV intravenous
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anaphylaxis [1, 5, 6, 78]. These criteria are validated for
use in EDs and other medical settings and in epidemio-
logical research, in which they are used to define study
populations. In order to operationalize them, illustrations
[1, 2, 19] and a color-coded chart [78] have been developed.
Under-diagnosis of anaphylaxis is common. Although
over 80 % of 7822 responders (most of whom were physi-
cians or allied healthcare professionals) correctly identified
anaphylaxis when given a case scenario of a patient with
cutaneous involvement, only 55 % recognized anaphylaxis
in a case without cutaneous involvement [79]. Import-
antly, diagnostic confusion has been reported in children
hospitalized for life-threatening asthma, some of whom
met diagnostic criteria for anaphylaxis [80].
Less common considerations in the differential diag-
nosis also need to be kept in mind, as in the following
examples: Anaphylaxis due to ruptured hydatid cyst can
occur in areas without endemic Echinococcus granulosus,
a reminder that untreated patients who have lived in en-
demic areas remain at life-long risk [81]. Idiopathic sys-
temic capillary leak syndrome has now been documented
in children aged 5–11 years; therefore, in the pediatric
population, as in adults, it should be considered in the dif-
ferential diagnosis of anaphylaxis in patients who present
with hypotension, shock, and fluid extravasation [82].
In addition, misdiagnosis or over-diagnosis of anaphyl-
axis can occur, as described in patients with acute multi-
system symptoms after ingestion of caustic substances,
and those with foreign body inhalation, acute urticaria,
or angioedema [83, 84].
Role of laboratory tests
Serum tryptase levels in blood samples taken 15–180 mi-
nutes after symptom onset can support the clinical diagno-
sis of anaphylaxis in some but not all patients [1, 5, 6]. In
food-induced anaphylaxis, single tryptase measurements
are typically within the normal reference range; however, in
these patients, use of a ratio (peak tryptase level divided by
basal level) is reported to improve sensitivity, specificity,
and positive and negative likelihood ratios [85].
In perioperative anaphylaxis, serum tryptase levels are
not compromised by large volumes of fluid or by resusci-
tation [86]. An elevated “acute” serum tryptase level (%
change >141 %; or absolute tryptase level of >15.7 mcg/L)
has been reported to be highly predictive of IgE-mediated
perioperative anaphylaxis in a multi-center, retrospective
analysis [87].
In post-mortem sera, serum tryptase levels can vary in
the same person depending on the site of blood sam-
pling; moreover, elevated levels are not specific for ana-
phylaxis, but can also occur in people who die from
myocardial infarction, asphyxia, or trauma [88].
Even when tryptase levels are within the normal refer-
ence range, other mediators of inflammation such as
histamine, PAF, PGD2, and LTE4 can be elevated in ana-
phylaxis [1–6]. Heparin, the contact system, and activation
of factor-XII are also involved in anaphylaxis, generating
plasma kallikrein that protealyzes kininogen and leads to
bradykinin release; moreover, the intensity of contact sys-
tem activation and bradykinin formation are associated
with anaphylaxis severity [89].
Reliance on elevation of only one mediator of inflam-
mation to confirm the clinical diagnosis of anaphylaxis
is likely insufficient. In a prospective controlled study of
ED patients with moderately severe anaphylaxis, gene
expression in peripheral blood samples was profiled in
microarrays, differentially expressed genes were identi-
fied, and network analysis was used to explore under-
lying mechanisms [90].
In these patients, on ED arrival, two genes were differ-
entially expressed. One hour post-arrival, 67 genes were
expressed; and three hours post-arrival, 2801 genes were
expressed. Network analysis demonstrated up-regulation
of three inflammatory modules, each containing multiple
hub-genes with a central role in the regulation of innate
inflammatory responses [90].
Genomic responses in anaphylaxis provide insight
into potential release of a cascade of mediators that
might play a role in escalation of anaphylaxis symp-
toms and signs [90].
Initial treatment of anaphylaxis
Anaphylaxis is a life-threatening medical emergency in
which prompt intervention is critical. Principles of treat-
ment remain unchanged [1]; however, recommendations
for treatment are based on evidence of increasingly high
quality [91–103] (Table 3).
International guidelines concur that epinephrine (adren-
aline) is the medication of first choice in anaphylaxis be-
cause it is the only medication that reduces hospitalization
and death. Its life-saving alpha-1 agonist vasoconstrictor ef-
fects prevent and relieve airway edema, hypotension, and
shock; its beta-1 agonist chronotropic and inotropic effects
increase the rate and force of cardiac contractions, and its
beta-2 agonist effects lead to bronchodilation and de-
creased mediator release [1, 5, 6, 78, 91–93].
Early injection of epinephrine in anaphylaxis, defined
as injection before ED arrival, can significantly reduce
the likelihood of hospital admission, as compared with
initial injection after ED arrival [92]. Delayed injection of
epinephrine has been reported in yet another large series
of anaphylaxis-related fatalities in which only 23 % of
the 92 individuals received it before cardiac arrest [93].
Although epinephrine injection rates remain low in
many EDs [94], use of protocols or order sets can signifi-
cantly improve injection rates [95].
Epinephrine is significantly less likely to be injected in
food-induced anaphylaxis than in venom-induced
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anaphylaxis [38]. Other reasons for failure to inject it in-
clude: not giving it because symptoms appear mild or
moderate, or there are perceived contraindications to it
(pregnancy, older age, or CVD) [95–97], or the patient
refuses it [98]. In fact, there are no absolute contraindi-
cations to epinephrine [1, 4–6].
More emphasis is needed on prompt recognition and
appropriate treatment of anaphylaxis by healthcare pro-
fessionals. In a 2013 study, although junior doctors’ abil-
ity to manage anaphylaxis was somewhat improved
compared with a similar study in a 2002 physician co-
hort, only one-third of them knew the correct dose and
route for epinephrine administration [84].
In an ED single-center retrospective observational co-
hort study of epinephrine safety, 58 % of 573 consecutive
patients received epinephrine for anaphylaxis. Only four
of 316 patients (1 %) who received an intramuscular
(IM) epinephrine injection (most doses administered
through an auto-injector) developed adverse events; in
contrast, three of 30 patients (10 %) who received IV
bolus epinephrine had adverse events. There were no
overdoses with IM injection, versus an overdose rate of
13 % after IV bolus administration. These data support
the safety of the IM route and suggest need for extreme
caution when IV bolus doses are administered [99].
International guidelines concur that H1-antihistamines,
H2-antihistamines, and glucocorticoids are second-line
[1, 6, 78] or even third-line [5] medications in anaphylaxis.
These medications are not life-saving and should not be
used as initial or sole treatment. A systematic review of
H2-antihistamines in anaphylaxis found no randomized
controlled trials (RCTs) that met the criteria for inclusion;
the H2-antihistamines had been studied in acute allergic
reactions in which skin symptoms predominated; most
(80 %) of the patients had no respiratory or cardiovascular
involvement and did not have anaphylaxis [100]. Gluco-
corticoids are typically administered to prevent biphasic
or protracted episodes of anaphylaxis and have little or no
effect on initial symptoms and signs [1, 5, 6, 78].
In a systematic review and meta-analysis of 27 obser-
vational studies, biphasic episodes occurred in 192
(4.7 %) of 4114 patients with anaphylaxis (range 0.4 % to
23.3 %) [101]. Patients with unknown triggers and those
presenting with hypotension were at increased risk;
those with food-induced anaphylaxis were at decreased
risk. These data suggest that routine prolonged monitor-
ing is unnecessary in patients whose anaphylaxis symp-
toms have resolved and that the duration of observation
should be risk-stratified according to the clinical charac-
teristics and severity of the episode [101].
Methylene blue, a selective nitric oxide cyclic GMP in-
hibitor, prevents vasodilation and can rapidly reverse the
course of anaphylaxis refractory to epinephrine, oxygen,
and IV fluid resuscitation. Use in anaphylaxis is based
on case reports and extrapolated from use in septic
shock. Limitations include adverse events and interfer-
ence with pulse oximetry [102].
In patients with life-threatening anaphylaxis, cardio-
vascular collapse, and cardiac arrest, extracorporeal
membrane oxygenation (ECMO) is reported to act as a
bridge to recovery [103].
Long-term management of anaphylaxis in community
settings: self-treatment
Treatment of anaphylaxis does not end with resolution
of an acute episode [1]. Aimed at decreasing anaphyl-
axis morbidity and mortality in community settings,
high-quality studies, including prospective studies of
epinephrine auto-injectors (EAIs) and of anaphylaxis
education, are being published [104–118] (Table 3).
Further studies of the long-term benefits of anaphylaxis
education are needed.
Allergy/immunology specialists clarified the diagnosis
or accurately identified and confirmed the specific ana-
phylaxis trigger in 35 % of patients referred from an
ED after treatment for anaphylaxis [104]. Visits to an
allergist/immunologist reduced the risk of severe ana-
phylaxis requiring hospital admission [17].
In many countries, EAIs are still unavailable [94].
Where they are available, they remain under-prescribed
and under-used; as an example, only 11 % of 261 indi-
viduals with a history of confirmed anaphylaxis had used
an EAI during their most recent episode, and 52 %
reported that they had never received an EAI prescrip-
tion [8, 105]. In another study, only 16 % of 102 patients
could demonstrate the correct use of an EpiPen; most
patients made at least one mistake and 56 % of them
missed three or more steps [106].
New EAIs are being developed and introduced. In the
US and Canada, the Auvi-Q is a user-friendly, uniquely-
shaped EAI (not a pen), with audio and visual prompts,
and needle protection before and after use [107]. Most
parents (93 %) who had never previously seen an Auvi-Q
or a demonstration of its use intuitively used it correctly
on their first attempt [108]. In Europe, the Emerade is
available in a 0.15, 0.3, and 0.5 mg dose, with a 16 mm
needle on the 0.15 mg EAI and a 25 mm (1-inch needle)
needle on the 0.3 mg EAI and the 0.5 mg EAI.
EAIs differ significantly with regard to size, ease of
carrying, ease of use, needle protection, and robustness.
They are not inter-changeable [107, 108].
However, manufacturers’ recommendations are similar
for all EAIs with regard to storage: keep at 20° to 25 °C
(excursions permitted from 15° to 30 °C) to protect the
epinephrine solution from degradation and ensure
mechanical integrity of the device. In a warm climate,
the degradation of epinephrine solution in EAIs is po-
tentially accelerated [109]. If EAIs are subjected to
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freezing temperatures for a few days, no degradation of
epinephrine solution occurs; however, they must be com-
pletely thawed before use [110].
Long-term follow-up is important to ensure retention of
skills by patients, caregivers, and healthcare professionals.
As an example,160 medical interns had theoretical train-
ing about anaphylaxis and practical demonstrations with
EpiPen trainers. They were then randomly assigned into
one group tested 3 months later and another group tested
6 months later. Test scores and EAI demonstration skills,
including mean time to “inject epinephrine” from EpiPen
trainers, were retained at 3 months, but decreased signifi-
cantly at 6 months [111].
Structured education programs improve anaphylaxis
management. In a prospective study, 98 patients with
a history of anaphylaxis and 95 caregivers received
two anaphylaxis education modules, each lasting three
hours. At follow-up 3 months later, those receiving
this intervention improved significantly in knowledge
and competence in emergency management, and
caregiver anxiety was reduced, as compared with
controls who received only standard auto-injector
training [112].
An anaphylaxis e-learning program for pharmacists de-
veloped by the Australian Society of Clinical Immunology
and Allergy was compared with lectures or no training at
all. Effectiveness was measured using a validated test ad-
ministered pre-training, immediately post-training, and
3 months and 7 months later. The proportion of e-
learners achieving the minimum standard for anaphylaxis
knowledge improved from 45 % at pre-test to 87 % at
7 months, confirming long-term improvement versus
comparators [113].
In many US schools, unassigned EAIs are now avail-
able for use in or by students who experience anaphyl-
axis and do not have a personal EAI available. Efforts to
reduce disparities in EAI availability within and between
school districts are ongoing [114].
Incorporation of prospectively validated pictograms
into a pediatric anaphylaxis emergency action plan po-
tentially increases comprehension of triggers, symptoms
and signs, and management [115].
A nurse delivered a training program in person to
4818 individuals at 247 schools and community sites.
Written evaluations, online surveys, and phone inter-
views were used to measure effectiveness. In-person
training increased participants’ knowledge and confi-
dence in prevention, recognition, and treatment of ana-
phylaxis [116].
In some countries, school staff are reported to have a
low level of preparedness to prevent and manage food-
induced allergic reactions [117]. Guidelines outlining a
standardized approach to risk management of patients
with food-induced allergic reactions in schools and
other community settings have been developed; how-
ever, RCTs of the effectiveness of the interventions are
needed to strengthen the evidence base for the recom-
mendations [118].
Long-term management: prevention of recurrence
Regular follow-up of all patients at risk of anaphylaxis
is an important principle of long-term risk reduction
[1, 5, 6]. High-quality studies, including RCTs that
focus on prevention of anaphylaxis are being pub-
lished [119–150] (Table 4).
Food-induced anaphylaxis
A detailed history of the anaphylactic episode is a critic-
ally important aspect of patient evaluation. In interpret-
ing the history, awareness of emerging new allergens
and cross-reactivity of homologous allergenic proteins is
helpful [39, 40, 119].
Based on a retrospective study, for predicting out-
comes of OFCs, the ratio of food-specific IgE to total
Table 4 Long-term management: trigger-specific prevention
Food-induced anaphylaxis [119–134]
Sustained clinical and immunological unresponsiveness to peanut was
documented after up to 5 years of peanut oral immunotherapy.
Responders had smaller skin test wheals and lower allergen-specific IgE
levels at baseline and at the time of post-treatment peanut challenge,
compared with non-responders [130].
Sustained clinical and immunological responsiveness to peanut has
been documented after up to 3 years of peanut sublingual immunotherapy.
Responders had a significant decrease in peanut-specific basophil
activation and skin prick test titration with peanut, as compared with
non-responders [131].
In selected high-risk infants with eczema, egg allergy, or both,
who were aged 4–10 months (inclusive) at study entry, early
introduction of peanut snacks (at least 6 grams weekly until
age 60 months) prevented development of clinical reactivity to
peanut [134].
Hymenoptera venom-induced anaphylaxis [135–139]
In 100 adults who completed venom immunotherapy and had live sting
challenges to prove efficacy, post-challenge scores on the Vespid Allergy
Quality of Life Questionnaire improved significantly, independent of age,
sex, or severity of the initial anaphylaxis episode [138].
Drug/iatrogenic agent-induced anaphylaxis [140–148]
In a retrospective study of patients with a history of hypersensitivity
reactions during anesthesia, comprehensive evaluation, including skin
tests and measurement of basal tryptase levels, followed by
development of a management plan, minimized risk of subsequent
reactions even when a specific trigger such as an antibiotic,
neuromuscular blocker, or latex was not identified [145].
Idiopathic anaphylaxis [149, 150]
In 20 % of 110 patients with idiopathic anaphylaxis (no identifiable
trigger by history, skin tests, or allergen-specific IgE levels), the etiology
of the episode was identified by using the ImmunoCAP ISAC 103
allergen array in addition to the ImmunoCAP 250 platform. Omega-5
gliadin and shrimp were the most frequently identified sensitizations
among those not previously recognized [149].
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IgE was more accurate than specific IgE levels alone in
confirming development of tolerance [120].
Component-resolved testing involves identifying spe-
cific IgE by using allergenic proteins derived from re-
combinant DNA technology or purified from natural
sources. Among 165 consecutive peanut-sensitized chil-
dren, those clinically reactive to peanut consistently had
significantly higher peanut-specific and Ara h 2-specific
IgE antibody levels than those who could tolerate peanut
ingestion [121].
Use of the BAT in peanut-sensitized children revealed
peanut concentration-dependent up-regulation of CD63
and CD203c in those who were clinically reactive to pea-
nut, contrasting with no significant responses in those
who could tolerate peanut ingestion. The BAT reduced
the number of OFCs required [122].
The 65–70 % of children destined to outgrow their
anaphylactic sensitivity to milk or egg cannot be accur-
ately identified by skin prick tests, nor can specific IgE
levels be interpreted as an absolute indication or contra-
indication to an OFC. However, many caregivers can re-
liably report that their cow’s milk- or egg-allergic child
already eats and tolerates baked goods such as muffins
containing small quantities of extensively-heated milk or
egg without developing symptoms. For other children,
such as a child who has been strictly avoiding cow’s milk
and related products, a physician-supervised cow’s milk
OFC is strongly recommended [119, 123–125].
Predictors of failure (clinical reactions, including ana-
phylaxis) during physician-supervised OFCs with baked
cow’s milk were: asthma, asthma requiring preventer
therapy, IgE-mediated clinical reactions to more than
three food groups, and a history of anaphylaxis to cow’s
milk [125].
A practical guide to managing cow’s milk allergy and/
or egg allergy includes recipes for muffins containing
baked milk or baked egg suitable for use in physician-
supervised OFCs in hospital settings and instructions for
continuing safe introduction of baked milk or baked egg
at home after a patient passes an OFC [124]. Useful
web-based resources are also available [119].
Adherence, defined as regular dietary consumption
of extensively heated cow’s milk or egg, has been
documented in two-thirds of children who passed a
physician-supervised OFC. Children with asthma ap-
pear to be at increased risk of ongoing reactivity
after passing an OFC [126].
Based on a validated disease-specific questionnaire,
OFCs, regardless of pass or fail outcome, were associated
with improved quality-of-life in caregivers of food-allergic
children, as compared with caregivers of food-allergic chil-
dren who did not have OFCs [127].
Liberalizing the diet is important for children who can
tolerate baked milk or baked egg because strict elimination
diets, particularly those excluding milk, have been associ-
ated with linear growth impairment and nutritional defi-
ciencies, exclusion from social activities, and higher direct
costs such as medications and indirect costs such as lost
wages and household expenses [128, 129].
RCTs confirm that desensitization can be achieved in
many patients who are symptomatic after ingestion of
highly allergenic foods such as peanut, milk, or egg [130,
131]. During OIT, patients with asthma are at risk for
more severe adverse events, including anaphylaxis [20],
and are less likely to achieve full desensitization than non-
asthmatics [132]. The safety of OIT can be improved by
omalizumab pre-treatment and co-treatment [40].
Sustained clinical unresponsiveness to peanut after
OIT has been demonstrated in a clinical trial in which
children aged 1–16 years were treated with dose in-
creases up to 4000 mg/day peanut protein. Double-blind
placebo-controlled OFCs with 5000 mg peanut protein
(on average, 12 peanuts) were conducted. Of 39 partici-
pants, 24 completed the protocol and 12 passed the
OFC 1 month after stopping treatment. This study con-
firmed sustained unresponsiveness after up to 5 years of
peanut OIT. Successful outcomes could be predicted by
smaller skin test wheals to peanut and lower peanut-
specific IgE levels at baseline and at the time of peanut
challenge [130]. In an experimental OIT model, IgG
antibodies that act through FcγRIIb to suppress IgE-
mediated hypersensitivity have been induced [133].
In a 3 year follow-up study of peanut sublingual im-
munotherapy, in OFCs performed 2 weeks after treatment
ended, 11 % of the 40 patients were able to consume 10
grams of peanut powder, equivalent to 16–18 peanuts.
Approximately 98 % of the 18,165 doses were tolerated
without severe symptoms beyond the oropharynx. At
year 2 of maintenance treatment, responders had a sig-
nificant decrease in peanut-specific basophil activation
and SPT titration compared with non-responders. By
study’s end, 10.8 % of 37 patients achieved sustained
unresponsiveness to peanut. The drop-out rate was
high, mainly due to difficulties in taking the sublingual
peanut extract every day [131].
Prevention of clinical reactivity to peanut may eventu-
ally be possible. In a landmark RCT, 640 infants with
severe eczema, egg allergy, or both, who were age 4–
10 months at study entry were assigned to either con-
sume peanuts or avoid peanuts until age 60 months.
Randomization was based on pre-existing sensitization
to peanut as determined by SPT. The primary outcome
was the proportion of children with peanut allergy at age
60 months. In the infants who avoided peanut, the
prevalence of peanut allergy was 13.7 %. In those who
consumed at least 6 grams of a peanut butter-containing
snack per week, it was significantly lower (1.9 %). In these
carefully selected high-risk infants, early introduction of
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peanut prevented subsequent development of clinical re-
activity to peanut [134]. Additional studies of prevention
strategies are ongoing.
Stinging insect-induced anaphylaxis
Venom immunotherapy (VIT) effectively reduces sus-
ceptible patients’ risk of recurrent SARs. The risk con-
tinues to decrease the longer VIT is continued. The
currently recommended duration of VIT is 5 years;
however, it should be given for more than 5 years to pa-
tients who are at particularly high risk for venom ana-
phylaxis, including the elderly, those with concomitant
cardiac and/or pulmonary disease, elevated basal serum
tryptase levels, and SARs before or during VIT. Life-
long VIT is the standard of care for patients with clonal
mast cell disorders [135]. Omalizumab can be used to
facilitate VIT in patients who previously could not tol-
erate it [136].
Because of the residual risk of SARs after VIT, all pa-
tients should carry EAIs indefinitely and continue to
avoid Hymenoptera stings [135]. When teaching patients
to avoid stinging insects and their nests, visual aids
should be used to aid in recognition [137].
Sting challenge with a live insect is the only test that
accurately evaluates VIT efficacy. In 100 adults who had
completed VIT, after their sting challenges, scores on
the Vespid Allergy Quality-of-Life Questionnaire im-
proved significantly, independent of sex, age, and sever-
ity of the initial anaphylactic episode [138].
In some areas of Australia, jack jumper ant stings are
an important cause of anaphylaxis and death. Jack
jumper ant VIT effectively prevents anaphylaxis recur-
rences. Its tolerability and safety are comparable with
those of honeybee VIT [139].
Drug-induced/iatrogenic anaphylaxis
In patients with a history of anaphylaxis to penicillins, if
at all possible, skin tests, even SPT, and challenge tests
should be avoided, because they can trigger anaphylaxis
[140, 141].
In contrast, many (90 %) low-risk penicillin allergy-
labeled patients who have no history of anaphylaxis or
other penicillin-associated serious life-threatening reac-
tions can be de-labeled using a risk stratification proto-
col developed to guide skin testing and challenge tests.
Compliance with recommendations for de-labeling can
be increased by improved communication with patients
and their physicians [142].
In 72 patients without HIV who had a history of
sulfonamide adverse drug reactions, the outcomes of
trimethoprim-sulfamethoxazole desensitization were
evaluated for safety and efficacy after graded adminis-
tration using short protocols (90 minutes to six hours),
one-day protocols, or longer protocols. Desensitization
was discontinued due to adverse reactions in only eight
patients [143].
Paracetamol, a weak COX inhibitor, rarely triggers
symptoms in patients with non-selective hypersensi-
tivity reactions to NSAIDs. Use of a provocation test
with paracetamol in children with a history of NSAID
allergy is reported to exclude paracetamol as an in-
ducer of anaphylaxis and identify it as a safe treat-
ment option [144].
A retrospective study supports a comprehensive evalu-
ation and management plan for patients with hypersen-
sitivity reactions during anesthesia. Of 72 such patients
referred to allergy/immunology, 18 % had positive skin
tests to beta-lactam antibiotics, neuromuscular blockers,
latex, or other agents. One patient who had an elevated
basal tryptase level was diagnosed with mastocytosis. On
follow-up, 96 % of the 47 patients requiring subsequent
anesthesia tolerated it uneventfully. The two patients
with recurrent reactions were later diagnosed with mast
cell disorders [145].
IgA-deficient individuals with anti-IgA antibodies
can develop anaphylaxis during transfusion of blood
or blood products. As compared with time-consuming
quantitative assays such as the fluorescein enzyme im-
munoassay, rapid non-quantitative DiaMed particle
gel immunoassays for identifying IgA-deficiency and
antibodies to IgA have reasonable sensitivity and spe-
cificity. They are potentially useful in emergency situa-
tions for diagnosing anti-IgA-related anaphylaxis and
identifying donors who can provide IgA-deficient
blood products [146].
Use of first-line chemotherapy and monoclonal
agents for malignancies and chronic inflammatory dis-
eases prolongs patient survival and minimizes morbidity.
Desensitization should be considered when patients de-
velop drug hypersensitivity to first-line agents and no
alternative therapies are available, or when alternative
treatments are considered to be therapeutically inferior
and/or more toxic. The indications, protocols, and out-
comes of desensitizations for chemotherapy and mono-
clonal antibodies in adults and children have been
reviewed [147].
Influenza vaccine should not be withheld from egg-
sensitized patients, even those with a history of egg-
induced anaphylaxis [148]. The egg content of 2015
influenza vaccines is below the threshold needed to
trigger reactions in egg-sensitized people. Injected and
intranasal influenza vaccines have been studied in
4315 patients with egg allergy, including 656 patients
with a history of anaphylaxis to ingested egg. The rare
patients with a history of urticaria or anaphylaxis after
immunization with influenza vaccine need an allergy/
immunology evaluation that includes skin tests to the
vaccine itself [148].
Simons et al. World Allergy Organization Journal  (2015) 8:32 Page 11 of 16
Idiopathic anaphylaxis
In idiopathic anaphylaxis, by definition, meticulous his-
tory, skin tests and measurement of allergen-specific IgE
levels have not revealed the trigger. In 20 % of 110 pa-
tients with previously diagnosed idiopathic anaphylaxis,
the etiology of the episode was identified by testing with
the ImmunoCAP ISAC 103 allergen array in addition to
the ImmunoCAP 250 platform. Omega-5 gliadin and
shrimp accounted for 45 % of the previously unrecognized
sensitizations. Clinical reassessment substantiated the
etiologic link in many patients [149].
In idiopathic anaphylaxis, there are no RCTs of inter-
ventions and no standardized treatment recommenda-
tions. Rituximab infusions induced remission of idiopathic
anaphylaxis in a patient who had anaphylaxis symptoms
every 3–30 days despite prophylaxis with high-dose H1-
and H2-antihistamines, a leukotriene antagonist, systemic
glucocorticoids, mycophenolate mofetil, omalizumab, and
a diet restricted to three foods [150].
Conclusions
The recommendations for the assessment, management
and prevention of anaphylaxis promulgated in the
2011 WAO Anaphylaxis Guidelines are supported and
strengthened year-on-year by publication of new, relevant,
epidemiological and experimental research findings, in-
cluding some RCTs.
Important advances in 2014–2015 comprised further
elucidation of patient risk factors and co-factors that
amplify anaphylaxis, and greater insights into anaphyl-
axis triggers such as food, venom, and drugs, as well as
idiopathic anaphylaxis. A prospective study documented
the genomic basis of anaphylaxis and the cascade of me-
diators released during innate immune system activation
in the first three hours after symptom onset.
High-quality observational studies published in 2014–
2015 have confirmed that prompt injection of epi-
nephrine reduces hospital admissions and that IM
epinephrine injections are 10-fold safer than IV bolus
injections. A study of anaphylaxis fatalities found that
23 % of those who died did not receive epinephrine
until cardiac arrest. New developments in long-term
management of anaphylaxis include novel EAIs, pro-
spective studies of anaphylaxis education, and sub-
stantial progress in use of immunomodulation to
prevent anaphylactic episodes.
Abbreviations
ACE: Angiotensin-converting enzyme; Alpha-gal: Galactose-alpha 1,3-galactose;
ASA: Acetylsalicylic acid; BAT: Basophil activation test; CVD: Cardiovascular
disease; EAI: Epinephrine auto-injector; ECMO: Extracorporeal membrane
oxygenation; ED: Emergency department; ICD: International Classification of
Diseases; ICON: Anaphylaxis: International Consensus on Anaphylaxis;
IM: Intramuscular; ISM: indolent systemic mastocytosis; IV: Intravenous;
MCAS: Mast cell activation syndrome; NMBA: Neuromuscular blocking agent;
NSAIDs: Non-steroidal anti-inflammatory drugs; OFC: Oral food challenge;
OIT: Oral immunotherapy; PAF: Platelet-activating factor;
RCM: Radiocontrast media; RCT: Randomized controlled trial;
SAR: Systemic allergic reaction; SPT: Skin prick tests; VIT: Venom
immunotherapy; WAO: World Allergy Organization.
Competing interests
F. Estelle R. Simons: FERS is on the following Medical Advisory Boards:
Allergopharma, Merck, Mylan, and Sanofi.
Motohiro Ebisawa: ME has no competing interests.
Mario Sanchez-Borges: Organizational: Member, Executive Committee, World
Allergy Organization; Financial: Honorarium for educational purposes from
Novartis Pharma AG.
Bernard Y. Thong: BYT has no competing interests.
Margitta Worm: MW is on the following Medical Advisory Boards: Mylan,
Meda Pharma GmbH, ALK-Abello Arzneimittel GmbH, Allergopharma GmbH
& Co., KG.
Luciana Kase Tanno: LKT has no competing interests.
Richard F. Lockey: RFL has no competing interests.
Yehia El-Gamal: YEG has no competing interests.
Simon G.A. Brown: SGAB has no competing interests.
Hae-Sim Park: HSP has no competing interests.
Aziz Sheikh: AS has no competing interests.
Authors’ contributions
FERS reviewed the anaphylaxis research published in peer-reviewed indexed
journals from January 2014 through mid-year 2015, led the development of
the 2015 Update, and prepared the initial, interim, and final drafts of the
manuscript. ME was involved in the selection of studies for inclusion in this
Update and commented critically on drafts of the manuscript. MSB was
involved in the selection of studies for inclusion in this Update and commented
critically on drafts of the manuscript. BYT was involved in the selection of
studies for inclusion in this Update and commented critically on drafts of
the manuscript. MW was involved in the selection of studies for inclusion
in this Update and commented critically on drafts of the manuscript. LKT
was involved in the selection of studies for inclusion in this Update and
commented critically on drafts of the manuscript. RFL was involved in the
selection of studies for inclusion in this manuscript and commented critically
on drafts of the manuscript. YEG was involved in the selection of studies
for inclusion in this manuscript. SGAB was involved in the selection of studies
for inclusion in this manuscript. HSP was involved in the selection of studies for
inclusion in this manuscript. AS was involved in the selection of studies for
inclusion in this Update and commented critically on drafts of the manuscript.
All authors are members of the WAO Anaphylaxis Committee, 2014–2015. All
authors read and approved the final manuscript.
Acknowledgments
We acknowledge the support of WAO President, Dr. Lanny J. Rosenwasser,
and the WAO Board of Directors. We also sincerely thank Lori McNiven,
Health Sciences Centre, Winnipeg, MB, Canada for expert assistance.
Author details
1Department of Pediatrics & Child Health and Department of Immunology,
College of Medicine, Faculty of Health Sciences, The University of Manitoba,
Room FE125, 820 Sherbrook Street, Winnipeg R3A 1R9 MB, Canada.
2Department of Allergy, Clinical Research Center for Allergy & Rheumatology,
Sagamihara National Hospital, Sagamihara, Kanagawa, Japan. 3Allergy and
Clinical Immunology Department, Centro Medico-Docente La Trinidad,
Caracas, Venezuela. 4Department of Rheumatology, Allergy & Immunology,
Tan Tock Seng Hospital, Singapore, Singapore. 5Allergie-Centrum-Charite,
Klinik fur Dermatologie, Venerologie und Allergologie, Campus Charite Mitte,
Universitatsmedizin, Berlin, Germany. 6Department of Allergy and Clinical
Immunology, Hospital Servidor Publico Estadual de Sao Paulo and Hospital
Sirio-Libanes, Sao Paulo, Brazil. 7University of South Florida College of
Medicine, Tampa, FL, USA. 8Pediatric Allergy and Immunology Unit,
Children’s Hospital, Ain Shams University, Cairo, Egypt. 9Royal Hobart
Hospital, Tasmania, and University of Western Australia and Royal Perth
Hospital, Perth, Western Australia. 10Department of Allergy & Clinical
Immunology, Ajou University School of Medicine, Seoul, South Korea.
11Allergy & Respiratory Research Group, Usher Institute of Population Health
Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
Simons et al. World Allergy Organization Journal  (2015) 8:32 Page 12 of 16
Received: 6 August 2015 Accepted: 25 September 2015
References
1. Simons FER, Ardusso LRF, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al. for
the World Allergy Organization. World Allergy Organization guidelines for
the assessment and management of anaphylaxis. J Allergy Clin Immunol.
2011;127:587–93. e1-e22.
2. Simons FER, Ardusso LRF, Bilo MB, Dimov V, Ebisawa M, El-Gamal YM, et al.
for the World Allergy Organization. 2012 Update: World Allergy Organization
(WAO) guidelines for the assessment and management of anaphylaxis.
Curr Opin Allergy Clin Immunol. 2012;12:389–99.
3. Simons FER, Ardusso LRF, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF,
et al. for the World Allergy Organization. World Allergy Organization
anaphylaxis guidelines: 2013 update of the evidence base. Int Arch
Allergy Immunol. 2013;162:193–204.
4. Simons FER, Ardusso LRF, Bilo MB, Cardona V, Ebisawa M, El-Gamal YM, et al.
International consensus on (ICON) anaphylaxis. WAO J. 2014;7:9.
5. Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al.
Anaphylaxis: guidelines from the European Academy of Allergy and Clinical
Immunology. Allergy. 2014;69:1026–45.
6. Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein
J, et al. Anaphylaxis – a practice parameter update 2015. Ann Allergy
Asthma Immunol. (in press).
7. Tejedor Alonso MA, Moro Moro M, Múgica García MV. Epidemiology of
anaphylaxis. Clin Exp Allergy. 2015;45:1027–39.
8. Wood RA, Camargo Jr CA, Lieberman P, Sampson HA, Schwartz LB, Zitt M,
et al. Anaphylaxis in America: The prevalence and characteristics of
anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:461–7.
9. Rudders SA, Arias SA, Camargo Jr CA. Trends in hospitalizations for food-
induced anaphylaxis in US children, 2000–2009. J Allergy Clin Immunol.
2014;134:960–2. e3.
10. Nocerino R, Leone L, Cosenza L, Canani RB. Increasing rate of hospitalizations
for food-induced anaphylaxis in Italian children: an analysis of the Italian
Ministry of Health database. J Allergy Clin Immunol. 2015;135:833–35. e3.
11. Mullins RJ, Dear KBG, Tang MLK. Time trends in Australian hospital anaphylaxis
admissions in 1998–1999 to 2011–2012. J Allergy Clin Immunol.
2015;136:367–75.
12. Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T,
et al. Increase in anaphylaxis-related hospitalizations but no increase in
fatalities: An analysis of United Kingdom national anaphylaxis data,
1992–2012. J Allergy Clin Immunol. 2015;135:956–63. e1.
13. Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with
anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:1075–83.
14. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the
United States, 1999–2010: Temporal patterns and demographic associations.
J Allergy Clin Immunol. 2014;134:1318–28. e7.
15. Tanno LK, Calderon MA, Goldberg BJ, Akdis CA, Papadopoulos NG,
Demoly P. Categorization of allergic disorders in the new World Health
Organization International Classification of Diseases. Clin Transl Allergy.
2014;4:42.
16. Tanno LK, Calderon MA, Goldberg BJ, Gayraud J, Bircher AJ, Casale T, et al.
Constructing a classification of hypersensitivity/allergic diseases for ICD-11
by crowdsourcing the allergist community. Allergy. 2015;70:609–15.
17. Clark S, Wei W, Rudders SA, Camargo Jr CA. Risk factors for severe
anaphylaxis in patients receiving anaphylaxis treatment in US emergency
departments and hospitals. J Allergy Clin Immunol. 2014;134:1125–30.
18. Ye YM, Kim MK, Kang HR, Kim TB, Sohn SW, Koh YI, et al. for the KAAACI
Work Group on Urticaria/Angioedema/Anaphylaxis. Predictors of the
severity and serious outcomes of anaphylaxis in Korean adults: a
multicenter retrospective case study. Allergy Asthma Immunol Res.
2015;7:22–9.
19. Simons FER, Sampson HA. Anaphylaxis: Unique aspects of clinical diagnosis
and management in infants (birth to age 2 years). J Allergy Clin Immunol.
2015;135:1125–31.
20. Vazquez-Ortiz M, Alvaro M, Piquer M, Giner MT, Dominguez O, Lozano J,
et al. Life-threatening anaphylaxis to egg and milk oral immunotherapy in
asthmatic teenagers. Ann Allergy Asthma Immunol. 2014;113:482–4.
21. Rutkowski K, Nasser SM. Management of hypersensitivity reactions to anti-D
immunoglobulin preparations. Allergy. 2014;69:1560–3.
22. Triggiani M, Montagni M, Parente R, Ridolo E. Anaphylaxis and
cardiovascular diseases: a dangerous liaison. Curr Opin Allergy Clin
Immunol. 2014;14:309–15.
23. Lieberman P, Simons FER. Anaphylaxis and cardiovascular disease:
therapeutic dilemmas. Clin Exp Allergy. 2015;45:1288–95.
24. Rueff F, Vos B, Oude Elberink J, Bender A, Chatelain R, Dugas-Breit S, et al.
Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
Clin Exp Allergy. 2014;44:736–46.
25. Stoevesandt J, Hain J, Stolze I, Kerstan A, Trautmann A. Angiotensin-
converting enzyme inhibitors do not impair the safety of Hymenoptera
venom immunotherapy build-up phase. Clin Exp Allergy. 2014;44:747–55.
26. Nassiri M, Babina M, Dölle S, Edenharter G, Ruëff F, Worm M. Ramipril and
metoprolol intake aggravate human and murine anaphylaxis: Evidence for
direct mast cell priming. J Allergy Clin Immunol. 2015;135:491–9.
27. Valent P. Risk factors and management of severe life-threatening
anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy.
2014;44:914–20.
28. Gulen T, Hagglund H, Sander B, Dahlen B, Nilsson G. The presence of mast
cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy.
2014;44:1179–87.
29. Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, Bonadonna P, Vega A,
Matito A, et al. Nonaggressive systemic mastocytosis (SM) without skin
lesions associated with insect-induced anaphylaxis shows unique
features versus other indolent SM. J Allergy Clin Immunol.
2014;133:520–8.
30. Broesby-Olsen S, Oropeza AR, Bindslev-Jensen C, Vestergaard H, Møller
MB, Siebenhaar F, et al. Recognizing mastocytosis in patients with
anaphylaxis: Value of KIT D816V mutation analysis of peripheral blood.
J Allergy Clin Immunol. 2015;135:262–4.
31. Fellinger C, Hemmer W, Wohrl S, Sesztak-Greinecker G, Jarisch R, Wantke F.
Clinical characteristics and risk profile of patients with elevated baseline
serum tryptase. Allergol Immunopathol (Madr). 2014;42:544–52.
32. Pravettoni V, Piantanida M, Primavesi L, Forti S, Pastorello EA. Basal
platelet-activating factor acetylhydrolase: Prognostic marker of
severe Hymenoptera venom anaphylaxis. J Allergy Clin Immunol.
2014;133:1218–20.
33. Lyons JJ, Sun G, Stone KD, Nelson C, Wisch L, O’Brien M, et al. Mendelian
inheritance of elevated serum tryptase associated with atopy and
connective tissue abnormalities. J Allergy Clin Immunol. 2014;133:1471–4.
34. Fischer J, Hebsaker J, Caponetto P, Platts-Mills TA, Biedermann T. Galactose-
alpha-1,3-galactose sensitization is a prerequisite for pork-kidney allergy and
cofactor-related mammalian meat anaphylaxis. J Allergy Clin Immunol.
2014;134:755–9. e1.
35. Ansley L, Bonini M, Delgado L, Del Giacco S, Du Toit G, Khaitov M, et al.
Pathophysiological mechanisms of exercise-induced anaphylaxis: an EAACI
position statement. Allergy. 2015;70:1212-21.
36. Brockow K, Kneissl D, Valentini L, Zelger O, Grosber M, Kugler C, et al.
Using a gluten oral food challenge protocol to improve diagnosis of
wheat-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol.
2015;135:977–84. e4.
37. Hox V, Desai A, Bandara G, Gilfillan AM, Metcalfe DD, Olivera A. Estrogen
increases the severity of anaphylaxis in female mice through enhanced
endothelial nitric oxide synthase expression and nitric oxide production.
J Allergy Clin Immunol. 2015;135:729–36. e5.
38. Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona
V, et al. First European data from the network of severe allergic reactions
(NORA). Allergy. 2014;69:1397–404.
39. Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis,
diagnosis, and treatment. J Allergy Clin Immunol. 2014;133:291–307.
40. Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, et al. Food
allergy: a practice parameter update - 2014. J Allergy Clin Immunol.
2014;134:1016–25. e43.
41. Umasunthar T, Leonardi-Bee J, Turner PJ, Hodes M, Gore C, Warner JO,
et al. Incidence of food anaphylaxis in people with food allergy: a
systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1621-1636.
42. Kamdar TA, Peterson S, Lau CH, Saltoun CA, Gupta RS, Bryce PJ. Prevalence
and characteristics of adult-onset food allergy. J Allergy Clin Immunol Pract.
2015;3:114–5. e1.
43. Vetander M, Ly DH, Hakansson N, Lilja G, Nilsson C, Ostblom E, et al.
Recurrent reactions to food among children at paediatric emergency
Simons et al. World Allergy Organization Journal  (2015) 8:32 Page 13 of 16
departments: epidemiology of allergic disease. Clin Exp Allergy.
2014;44:113–20.
44. van der Valk JPM, Dubois AEJ, Gerth van Wijk R, Wichers HJ, de Jong NW.
Systematic review on cashew nut allergy. Allergy. 2014;69:692–8.
45. Commins SP, James HR, Stevens W, Pochan SL, Land MH, King C, et al. Delayed
clinical and ex vivo response to mammalian meat in patients with IgE to
galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2014;134:108–15.
46. Takahashi K, Taniguchi M, Fukutomi Y, Sekiya K, Watai K, Mitsui C, et al. Oral
mite anaphylaxis caused by mite-contaminated okonomiyaki/pancake-mix
in Japan: 8 case reports and a review of 28 reported cases. Allergol Int.
2014;63:51–6.
47. Kelso JM. Potential food allergens in medications. J Allergy Clin Immunol.
2014;133:1509–18.
48. Levy Y, Segal N, Nahum A, Marcus N, Garty BZ. Hypersensitivity to
methylprednisolone sodium succinate in children with milk allergy.
J Allergy Clin Immunol Pract. 2014;2:471–4.
49. Hamilton RG, Scheer DI, Gruchalla R, Adkinson NF, Sampson HA. Casein-related
anaphylaxis after use of an Everlast kickboxing glove. J Allergy Clin Immunol.
2015;135:269–71.
50. Golden DB. New directions in diagnostic evaluation of insect allergy.
Curr Opin Allergy Clin Immunol. 2014;14:334–9.
51. Casale TB, Burks AW. Hymenoptera-sting hypersensitivity. N Engl J Med.
2014;370:1432–9.
52. Sturm GJ, Kranzelbinder B, Schuster C, Sturm EM, Bokanovic D, Vollmann J,
et al. Sensitization to Hymenoptera venoms is common, but systemic sting
reactions are rare. J Allergy Clin Immunol. 2014;133:1635–43. e1.
53. Cifuentes L, Vosseler S, Blank S, Seismann H, Darsow U, Bredehorst R, et al.
Identification of Hymenoptera venom-allergic patients with negative specific
IgE to venom extract by using recombinant allergens. J Allergy Clin Immunol.
2014;133:909–10.
54. Kohler J, Blank S, Muller S, Bantleon F, Frick M, Huss-Marp J, et al. Component
resolution reveals additional major allergens in patients with honeybee venom
allergy. J Allergy Clin Immunol. 2014;133:1383–9. e6.
55. Banerji A, Rudders S, Clark S, Wei W, Long AA, Camargo Jr CA. Retrospective
study of drug-induced anaphylaxis treated in the emergency department or
hospital: patient characteristics, management, and 1-year follow-up. J Allergy
Clin Immunol Pract. 2014;2:46–51.
56. Jares EJ, Sánchez-Borges M, Cardona-Villa R, Ensina LF, Arias-Cruz A, Gómez
M, et al. Multinational experience with hypersensitivity drug reactions in
Latin America. Ann Allergy Asthma Immunol. 2014;113:282–9.
57. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA,
et al. International consensus on drug allergy. Allergy. 2014;69:420–37.
58. Macy E, Contreras R. Health care use and serious infection prevalence
associated with penicillin “allergy” in hospitalized patients: A cohort study.
J Allergy Clin Immunol. 2014;133:790–6.
59. Li M, Krishna MT, Razaq S, Pillay D. A real-time prospective evaluation of
clinical pharmaco-economic impact of diagnostic label of “penicillin allergy”
in a UK teaching hospital. J Clin Pathol. 2014;67:1088–92.
60. Fox SJ, Park MA. Penicillin skin testing is a safe and effective tool for
evaluating penicillin allergy in the pediatric population. J Allergy Clin
Immunol Pract. 2014;2:439–44.
61. Macy E, Contreras R. Adverse reactions associated with oral and parenteral
use of cephalosporins: A retrospective population-based analysis. J Allergy
Clin Immunol. 2015;135:745–52.
62. Gaeta F, Valluzzi RL, Alonzi C, Maggioletti M, Caruso C, Romano A.
Tolerability of aztreonam and carbapenems in patients with IgE-mediated
hypersensitivity to penicillins. J Allergy Clin Immunol. 2015;135:972–6.
63. Uyttebroek AP, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Moxifloxacin
hypersensitivity: uselessness of skin testing. J Allergy Clin Immunol Pract.
2015;3:443–5.
64. Mori F, Pecorari L, Pantano S, Rossi ME, Pucci N, De Martino M, et al. Azithromycin
anaphylaxis in children. Int J Immunopathol Pharmacol. 2014;27:121–6.
65. Aun MV, Blanca M, Garro LS, Ribeiro MR, Kalil J, Motta AA, et al. Nonsteroidal
anti-inflammatory drugs are major causes of drug-induced anaphylaxis.
J Allergy Clin Immunol Pract. 2014;2:414–20.
66. Faria E, Rodrigues-Cernadas J, Gaspar A, Botelho C, Castro E, Lopes A,
et al. Drug-induced anaphylaxis survey in Portuguese allergy departments.
J Investig Allergol Clin Immunol. 2014;24:40–8.
67. Picaud J, Beaudouin E, Renaudin JM, Pirson F, Metz-Favre C, Dron-Gonzalvez
M, et al. Anaphylaxis to diclofenac: nine cases reported to the Allergy
Vigilance Network in France. Allergy. 2014;69:1420–3.
68. Craig TJ, Li H, Riedl M, Bernstein JA, Lumry WR, MacGinnitie AJ, et al.
Characterization of anaphylaxis after ecallantide treatment of hereditary
angioedema attacks. J Allergy Clin Immunol Pract. 2015;3:206–12.
69. Galvao VR, Castells MC. Hypersensitivity to biological agents – updated
diagnosis, management, and treatment. J Allergy Clin Immunol Pract.
2015;3:175–85.
70. Savic LC, Kaura V, Yusaf M, Hammond-Jones AM, Jackson R, Howell S, et al.
Incidence of suspected perioperative anaphylaxis: A multicenter snapshot
study. J Allergy Clin ImmunolPract. 2015;3:454–5. e1.
71. Reitter M, Petitpain N, Latarche C, Cottin J, Massy N, Demoly P, et al.
Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and
management analysis. Allergy. 2014;69:954–9.
72. Tsur A, Kalansky A. Hypersensitivity associated with sugammadex
administration: a systematic review. Anaesthesia. 2014;69:1251–7.
73. Opstrup MS, Malling HJ, Kroigaard M, Mosbech H, Skov PS, Poulsen LK, et al.
Standardized testing with chlorhexidine in perioperative allergy – a large
single-centre evaluation. Allergy. 2014;69:1390–6.
74. Péer L, Brezis ML, Shalit M, Carvalho B, Levin PD, Seri O, et al. Evaluation of a
prospectively administered written questionnaire to reduce the incidence of
suspected latex anaphylaxis during elective cesarean delivery. Int J Obstet
Anesth. 2014;23:335–40.
75. Kim MH, Lee SY, Lee SE, Yang MS, Jung JW, Park CM, et al. Anaphylaxis to
iodinated contrast media: clinical characteristics related with development
of anaphylactic shock. PLoS One. 2014;9:e100154.
76. Raisch DW, Garg V, Arabyat R, Shen X, Edwards BJ, Miller FH, et al.
Anaphylaxis associated with gadolinium-based contrast agents: data from
the Food and Drug Administration’s adverse event reporting system and
review of case reports in the literature. Expert Opin Drug Saf. 2014;13:15–23.
77. Ha SO, Kim DY, Sohn CH, Lim KS. Anaphylaxis caused by intravenous
fluorescein: clinical characteristics and review of literature. Intern Emerg Med.
2014;9:325–30.
78. Campbell RL, Li JT, Nicklas RA, Sadosty AT. Emergency department diagnosis
and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma
Immunol. 2014;113:599–608.
79. Wang J, Young MC, Nowak-Węgrzyn A. International survey of knowledge
of food-induced anaphylaxis. Pediatr Allergy Immunol. 2014;25:644–50.
80. Sargant N, Erlewyn-Lajeunesse M, Benger J. Does anaphylaxis masquerade
as asthma in children? Emerg Med J. 2015;32:83–4.
81. Murali MR, Uyeda JW, Tingpej B. Case 2–2015: a 25-year-old man with
abdominal pain, syncope, and hypotension. N Engl J Med. 2015;372:265–73.
82. Hsu P, Xie Z, Frith K, Wong M, Kakakios A, Stone KD, et al. Idiopathic
systemic capillary leak syndrome in children. Pediatrics. 2015;135:e730–5.
83. Sherenian MG, Clee M, Schondelmeyer AC, de Alarcon A, Li J, Assa’ad A,
et al. Caustic ingestions mimicking anaphylaxis: case studies and literature
review. Pediatrics. 2015;135:e547–50.
84. Plumb B, Bright P, Gompels MM, Unsworth DJ. Correct recognition and
management of anaphylaxis: not much change over a decade. Postgrad
Med J. 2015;91:3–7.
85. Wongkaewpothong P, Pacharn P, Sripramong C, Boonchoo S,
Piboonpocanun S, Visitsunthorn N, et al. The utility of serum tryptase
in the diagnosis of food-induced anaphylaxis. Allergy Asthma Immunol
Res. 2014;6:304–9.
86. Laroche D, Gomis P, Gallimidi E, Malinovsky JM, Mertes PM. Diagnostic value
of histamine and tryptase concentrations in severe anaphylaxis with shock
or cardiac arrest during anesthesia. Anesthesiology. 2014;121:272–9.
87. Krishna MT, York M, Chin T, Gnanakumaran G, Heslegrave J, Derbridge C,
et al. Multi-centre retrospective analysis of anaphylaxis during general
anaesthesia in the United Kingdom: aetiology and diagnostic performance
of acute serum tryptase. Clin Exp Immunol. 2014;178:399–404.
88. McLean-Tooke A, Goulding M, Bundell C, White J, Hollingsworth P. Post-
mortem serum tryptase levels in anaphylactic and non-anaphylactic deaths.
J Clin Pathol. 2014;67:134–8.
89. Sala-Cunill A, Bjorkqvist J, Senter R, Guilarte M, Cardona V, Labrador M, et al.
Plasma contact system activation drives anaphylaxis in severe mast cell-
mediated allergic reactions. J Allergy Clin Immunol. 2015;135:1031–43. e6.
90. Stone SF, Bosco A, Jones A, Cotterell CL, van Eeden PE, Arendts G,
et al. Genomic responses during acute human anaphylaxis are
characterized by upregulation of innate inflammatory gene networks.
PLoS One. 2014;9:e101409.
91. Dhami S, Panesar SS, Roberts G, Muraro A, Worm M, Bilò MB, et al.
Management of anaphylaxis: a systematic review. Allergy. 2014;69:168–75.
Simons et al. World Allergy Organization Journal  (2015) 8:32 Page 14 of 16
92. Fleming JT, Clark S, Camargo CA, Rudders SA. Early treatment of food-
induced anaphylaxis with epinephrine is associated with a lower risk of
hospitalization. J Allergy Clin Immunol Pract. 2015;3:57–62.
93. Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S. Anaphylaxis-related
deaths in Ontario: a retrospective review of cases from 1986 to 2011.
Allergy Asthma Clin Immunol. 2014;10:38.
94. Hitti EA, Zaitoun F, Harmouche E, Saliba M, Mufarrij A. Acute allergic
reactions in the emergency department: characteristics and management
practices. Eur J Emerg Med. 2015;22:253–9.
95. Manivannan V, Hess EP, Bellamkonda VR, Nestler DM, Bellolio MF, Hagan JB,
et al. A multifaceted intervention for patients with anaphylaxis increases
epinephrine use in adult emergency department. J Allergy Clin Immunol
Pract. 2014;2:294–9. e1.
96. Asai Y, Yanishevsky Y, Clarke A, La Vieille S, Delaney JS, Alizadehfar R,
et al. Rate, triggers, severity and management of anaphylaxis in adults
treated in a Canadian emergency department. Int Arch Allergy
Immunol. 2014;164:246–52.
97. Chung T, Gaudet L, Vandenberghe C, Couperthwaite S, Sookram S, Liss K,
et al. Pre-hospital management of anaphylaxis in one Canadian urban
centre. Resuscitation. 2014;85:1077–82.
98. Manivannan V, Hyde RJ, Hankins DG, Bellolio MF, Fedko MG, Decker WW,
et al. Epinephrine use and outcomes in anaphylaxis patients transported by
emergency medical services. Am J Emerg Med. 2014;32:1097–102.
99. Campbell RL, Bellolio MF, Knutson BD, Bellamkonda VR, Fedko MG,
Nestler DM, et al. Epinephrine in anaphylaxis: higher risk of
cardiovascular complications and overdose after administration of
intravenous bolus epinephrine compared with intramuscular
epinephrine. J Allergy Clin Immunol Pract. 2015;3:76–80.
100. Nurmatov UB, Rhatigan E, Simons FER, Sheikh A. H2-antihistamines for the
treatment of anaphylaxis with and without shock: a systematic review.
Ann Allergy Asthma Immunol. 2014;112:126–31.
101. Lee S, Bellolio MF, Hess EP, Erwin P, Murad MH, Campbell RL. Time of onset
and predictors of biphasic anaphylactic reactions: a systematic review and
meta-analysis. J Allergy Clin Immunol Pract. 2015;3:408–16.
102. Lo JCY, Darracq MA, Clark RF. A review of methylene blue treatment for
cardiovascular collapse. J Emerg Med. 2014;46:670–9.
103. Zhang Z, Su X, Liu C. Cardiac arrest with anaphylactic shock: a successful
resuscitation using extracorporeal membrane oxygenation. Am J Emerg Med.
2015;33:130.e3-4.
104. Campbell RL, Park MA, Kueber MA, Lee S, Hagan JB. Outcomes of allergy/
immunology follow-up after an emergency department evaluation for
anaphylaxis. J Allergy Clin Immunol Pract. 2015;3:88–93.
105. Altman AM, Camargo CA, Simons FER, Lieberman P, Sampson HA,
Schwartz LB, et al. Anaphylaxis in America: a national physician survey.
J Allergy Clin Immunol. 2015;135:830–3.
106. Bonds RS, Asawa A, Ghazi AI. Misuse of medical devices: a persistent
problem in self-management of asthma and allergic disease. Ann Allergy
Asthma Immunol. 2015;114:74–6.
107. Edwards ES, Edwards ET, Simons FER, North R. Drug-device combination
products in the 21st century: development using a human factors
engineering approach. Expert Opin Drug Deliv. 2015;12:751–62.
108. Umasunthar T, Procktor A, Hodes M, Smith JG, Gore C, Cox HE, et al.
Patients’ ability to treat anaphylaxis using adrenaline auto-injectors:
a randomized controlled trial. Allergy. 2015;70:855–63.
109. Rachid O, Simons FER, Wein MB, Rawas-Qalaji M, Simons KJ. Epinephrine
doses contained in outdated epinephrine auto-injectors collected in a
Florida allergy practice. Ann Allergy Asthma Immunol. 2015;114:354–6. e1.
110. Rachid O, Simons FER, Rawas-Qalaji M, Lewis S, Simons KJ. Epinephrine
autoinjectors: does freezing or refrigeration affect epinephrine dose delivery
and enantiomeric purity? J Allergy Clin Immunol Pract. 2015;3:294–6.
111. Topal E, Bakirtas A, Yilmaz O, Karagol IHE, Arga M, Demirsoy MS, et al. When
should we perform a repeat training on adrenaline auto-injector use for
physician trainees? Allergol Immunopathol (Madr). 2014;42:472–5.
112. Brockow K, Schallmayer S, Beyer K, Biedermann T, Fischer J, Gebert N, et al.
including the working group on anaphylaxis training education (AGATE).
Effects of a structured educational intervention on knowledge and
emergency management in patients at risk for anaphylaxis. Allergy.
2015;70:227–35.
113. Salter SM, Vale S, Sanfilippo FM, Loh R, Clifford RM. Long-term effectiveness
of online anaphylaxis education for pharmacists. Am J Pharm Educ.
2014;78:136.
114. Zadikoff EH, Whyte SA, DeSantiago-Cardenas L, Harvey-Gintoft B, Gupta RS.
The development and implementation of the Chicago public schools
emergency EpiPen policy. J Sch Health. 2014;84:342–7.
115. Mok G, Vaillancourt R, Irwin D, Wong A, Zemek R, Alqurashi W. Design
and validation of pictograms in a pediatric anaphylaxis action plan. Pediatr
Allergy Immunol. 2015;26:223–33.
116. Wahl A, Stephens H, Ruffo M, Jones AL. The evaluation of a food allergy and
epinephrine autoinjector training program for personnel who care for
children in schools and community settings. J Sch Nurs. 2015;31:91–8.
117. Le TM, Kummeling I, Dixon D, Tolosa LB, Ballmer-Weber B, Clausen M, et al.
Low preparedness for food allergy as perceived by school staff: a EuroPrevall
survey across Europe. J Allergy Clin Immunol Pract. 2014;2:480–2. e1.
118. Muraro A, Agache I, Clark A, Sheikh A, Roberts G, Akdis CA, et al. EAACI
Food Allergy and Anaphylaxis Guidelines: managing patients with food
allergy in the community. Allergy. 2014;69:1046–57.
119. Bird JA, Lack G, Perry TT. Clinical management of food allergy. J Allergy Clin
Immunol Pract. 2015;3:1–11.
120. Gupta RS, Lau CH, Hamilton RG, Donnell A, Newhall KK. Predicting outcomes
of oral food challenges by using the allergen-specific IgE—total IgE ratio.
J Allergy Clin Immunol Pract. 2014;2:300–5.
121. Ebisawa M, Moverare R, Sato S, Borres MP, Ito K. The predictive relationship
between peanut- and Ara h2-specific serum IgE concentrations and peanut
allergy. J Allergy Clin Immunol Pract. 2015;3:131–2. e1.
122. Santos AF, Douiri A, Bécares N, Wu SY, Stephens A, Radulovic S, et al.
Basophil activation test discriminates between allergy and tolerance in
peanut-sensitized children. J Allergy Clin Immunol. 2014;134:645–52.
123. Turner PJ, Kumar K, Fox AT. Skin testing with raw egg does not predict
tolerance to baked egg in egg-allergic children. Pediatr Allergy Immunol.
2015;25:657–61.
124. Leonard SA, Caubet JC, Kim JS, Groetch M, Nowak-Wegrzyn A. Baked milk- and
egg-containing diet in the management of milk and egg allergy.
J Allergy Clin Immunol Pract. 2015;3:13–23.
125. Mehr S, Turner PJ, Joshi P, Wong M, Campbell DE. Safety and clinical
predictors of reacting to extensively heated cow’s milk challenge in cow’s
milk-allergic children. Ann Allergy Asthma Immunol. 2014;113:425–9.
126. Lee E, Mehr S, Turner PJ, Joshi P, Campbell DE. Adherence to
extensively heated egg and cow’s milk after successful oral food
challenge. J Allergy Clin Immunol Pract. 2015;3:125–7. e4.
127. Franxman TJ, Howe L, Teich E, Greenhawt MJ. Oral food challenge and
food allergy quality of life in caregivers of children with food allergy.
J Allergy Clin Immunol Pract. 2015;3:50–6.
128. Mehta H, Ramesh M, Feuille E, Groetch M, Wang J. Growth comparison
in children with and without food allergies in 2 different demographic
populations. J Pediatr. 2014;165:842–8.
129. Protudjer JLP, Jansson SA, Arnlind MH, Bengtsson U, Kallstrom-Bengtsson I,
Marklund B, et al. Household costs associated with objectively diagnosed
allergy to staple foods in children and adolescents. J Allergy Clin Immunol
Pract. 2015;3:68–75.
130. Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP,
et al. Sustained unresponsiveness to peanut in subjects who have
completed peanut oral immunotherapy. J Allergy Clin Immunol.
2014;133:468–75. e6.
131. Burks AW, Wood RA, Jones SM, Sicherer SH, Fleischer DM, Scurlock
AM, et al. Sublingual immunotherapy for peanut allergy: long-term
follow-up of a randomized multicenter trial. J Allergy Clin Immunol.
2015;135:1240–8.
132. Elizur A, Goldberg MR, Levy MB, Nachshon L, Katz Y. Oral immunotherapy in
cow’s milk allergic patients: course and long-term outcome according to
asthma status. Ann Allergy Asthma Immunol. 2015;114:240–4.
133. Burton OT, Logsdon SL, Zhou JS, Medina-Tamayo J, Abdel-Gadir A, Rivas
MN, et al. Oral immunotherapy induces IgG antibodies that act through
FcγRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol.
2014;134:1310–7.
134. Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al.
Randomized trial of peanut consumption in infants at risk for peanut
allergy. N Engl J Med. 2015;372:803–13.
135. Muller UR, Ring J. When can immunotherapy for insect sting allergy be
stopped? J Allergy Clin Immunol Pract. 2015;3:324–8.
136. Palgan K, Bartuzi Z, Gotz-Zbikowska M. Treatment with a combination of
omalizumab and specific immunotherapy for severe anaphylaxis after a
wasp sting. Int J Immunopathol Pharmacol. 2014;27:109–12.
Simons et al. World Allergy Organization Journal  (2015) 8:32 Page 15 of 16
137. Baker TW, Forester JP, Johnson ML, Stolfi A, Stahl MC. The HIT study:
Hymenoptera Identification Test – how accurate are people at identifying
stinging insects? Ann Allergy Asthma Immunol. 2014;113:267–70.
138. Koschel DS, Schmies M, Weber CN, Hoffken G, Balck F. Tolerated sting
challenge in patients on Hymenoptera venom immunotherapy improves
health-related quality of life. J Investig Allergol Clin Immunol. 2014;24:226–30.
139. Mullins RJ, Brown SGA. Ant venom immunotherapy in Australia: the unmet
need. Med J Aust. 2014;201:33–4.
140. Syrigou E, Syrigos K. Anaphylaxis during skin prick testing for amoxicillin
allergy. J Allergy Clin Immunol Pract. 2014;2:478–9.
141. Park MA, Solensky R, Khan DA, Castells MC, Macy EM, Lang DM. Patients
with positive skin test results to penicillin should not undergo penicillin or
amoxicillin challenge. J Allergy Clin Immunol. 2015;135:816–7.
142. Bourke J, Pavlos R, James I, Phillips E. Improving the effectiveness of
penicillin allergy de-labeling. J Allergy Clin Immunol Pract. 2015;3:365–74.
143. Pyle RC, Butterfield JH, Volcheck GW, Podjasek JC, Rank MA, Li JTC, et al.
Successful outpatient graded administration of trimethoprim-
sulfamethoxazole in patients without HIV and with a history of sulfonamide
adverse drug reaction. J Allergy Clin Immunol Pract. 2014;2:52–8.
144. Ensina LF, de Lacerda AE, de Andrade DM, Machado L, Camelo-Nunes I,
Solé D. Drug-induced anaphylaxis in children: Nonsteroidal anti-inflammatory
drugs and drug provocation test. J Allergy Clin Immunol Pract. 2014;2:825.
145. Guyer AC, Saff RR, Conroy M, Blumenthal KG, Camargo CA, Long AA,
et al. Comprehensive allergy evaluation is useful in the subsequent
care of patients with drug hypersensitivity reactions during anesthesia.
J Allergy Clin Immunol Pract. 2015;3:94–100.
146. Oltean S, Epure A, Lindstrom K, Pardi C. Detection of anti-IgA antibodies
using the particle gel immunoassay: a rapid test for increased patient safety.
Blood Transfus. 2014;12:334–9.
147. Hong DI, Dioun AF. Indications, protocols, and outcomes of drug
desensitizations for chemotherapy and monoclonal antibodies in adults
and children. J Allergy Clin Immunol Pract. 2014;2:13–9.
148. Kelso JM. Influenza vaccine and egg allergy: nearing the end of an
evidence-based journey. J Allergy Clin Immunol Pract. 2015;3:140–1.
149. Heaps A, Carter S, Selwood C, Moody M, Unsworth J, Deacock S, et al.
The utility of the ISAC allergen array in the investigation of idiopathic
anaphylaxis. Clin Exp Immunol. 2014;177:483–90.
150. Borzutzky A, Morales PS, Mezzano V, Nussbaum S, Burks AW. Induction of
remission of idiopathic anaphylaxis with rituximab. J Allergy Clin Immunol.
2014;134:981–3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Simons et al. World Allergy Organization Journal  (2015) 8:32 Page 16 of 16
